Commercialising academic research in regenerative medicine.

Spun out of the University of Leeds in 2006, Tissue Regenix commercialise research undertaken by our higher education and research partners around the world. Tissue Regenix listed on the Alternative Investment Market (AIM) on the London Stock Exchange in 2010, before opening the first subsidiary office Tissue Regenix Woundcare, Inc. in San Antonio, Texas in 2012. In 2017 Tissue Regenix also completed the successful acquisition of CellRight Technologies, based in San Antonio, Texas.

US $81BN

Expected value of the Global Regenerative Medicine Market by 20231

You may also be interested in